Oppenheimer raised the firm’s price target on Capricor Therapeutics (CAPR) to $54 from $22 and keeps an Outperform rating on the shares following deramiocel’s broadly positive Phase 3 results and the company’s financing. The firm believes deramiocel’s clinical profile stands second to none relative to approved Duchenne muscular dystrophy therapeutics, and its projected 2031 sales of about $1.1B in the U.S. alone through partner NS Pharma may prove conservative.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics Announces $150 Million Public Offering
- Capricor Therapeutics 6M share Spot Secondary priced at $25.00
- Capricor TBA Spot Secondary; shares are being re-offered at $25.00
- Capricor Therapeutics announces common stock offering, no amount given
- Capricor Therapeutics price target raised to $50 from $25 at Maxim